Desethyloxybutynin clinical trials
Also written NRX-101.
How each study uses desethyloxybutynin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the desethyloxybutynin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NRX-101
- 4
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
NeuroRx, Inc. (4) · Mclean Hospital (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test desethyloxybutynin.
- Dec 2026Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101Early Phase 1 · Mclean Hospital
Studies
Open first, then newest update. How each study uses desethyloxybutynin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101RecruitingEarly Phase 1Mclean HospitalNCT07785102Written as NRX-101
- A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS TrialRecruitingPhase 2/3NeuroRx, Inc.NCT07227103Written as NRX-101
- NRX-101 for Bipolar Depression With Subacute Suicidal IdeationCompletedPhase 2/3NeuroRx, Inc.NCT03395392Written as NRX-101
- NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal IdeationActive, not recruitingPhase 3NeuroRx, Inc.NCT03396068Written as NRX-101
- Sequential Therapy for the Treatment of Severe Bipolar Depression.CompletedPhase 2NeuroRx, Inc.NCT02974010Written as NRX-101 Oral Capsule
Given beside what is tested · 1 — desethyloxybutynin is usual care or a partner of the new treatment
Codes
What other systems call desethyloxybutynin · ClinicalTrials.gg INT002983
- MeSH (NLM) C032681desethyloxybutyninOne source NLM
- UNII (FDA) 8809SNK4F7N-DESETHYLOXYBUTYNINConfirmed NLM, Wikidata
- Wikidata Q27269871N-desethyloxybutyninConfirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C032681 | desethyloxybutynin | One source NLM |
| UNII (FDA) | 8809SNK4F7 | N-DESETHYLOXYBUTYNIN | Confirmed NLM, Wikidata |
| Wikidata | Q27269871 | N-desethyloxybutynin | Confirmed NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.